PRELUDE THERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 72.61K shares.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 26.46K shares.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 3.41K shares.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 8.90K shares, a 30.89% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 12.31K shares, a 17.65% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 14.96K shares, a 44.40% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 26.90K shares, a 87.66% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 217.91K shares, a 78.12% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 72.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 111.38K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 26.46K shares 10-Q · filed 2026-05-12 | |
| 2025-12-31 | 3.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 12.31K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 8.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 14.96K shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 12.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 24.17K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | 900.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 11.28K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | 1.17K shares 10-Q · filed 2024-05-07 | 12.10K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | 9.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 26.90K shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 33.01K shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-06-30 | 1.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 111.31K shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-03-31 | 15.97K shares 10-Q · filed 2023-05-08 | 140.85K shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-12-31 | 15.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 217.91K shares 10-K · filed 2024-02-15 |
| 2022-09-30 | 78.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 587.40K shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | 31.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 662.17K shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | 93.03K shares 10-Q · filed 2022-05-10 | 878.71K shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | 384.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 995.95K shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 153.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 613.41K shares derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | 247.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 210.27K shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 2.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 100.55K shares 10-K · filed 2022-03-17 |
| 2019-12-31 | 19.67K shares 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |